Form 4: Zura Bio Director, Jennifer Jarrett, Acquires 51,000 Share Options

Director Jennifer Jarrett acquired 51,000 share options in Zura Bio Ltd on May 21, 2025, according to a Form 4 filing.

Summary

• Jennifer Jarrett, a director of Zura Bio Ltd, filed a Form 4 indicating a transaction involving derivative securities.
• On May 21, 2025, Jarrett acquired 51,000 share options with an exercise price of $1.03.
• These options vest in twelve equal monthly installments over one year from the grant date, with any remaining unvested portion vesting before the next annual shareholder meeting, contingent on continued service.
• Following the transaction, Jarrett directly owns 51,000 share options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by a director is mildly positive, suggesting confidence, but not significantly impactful.

Positives

• The acquisition of share options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of share options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Zura Bio, Share Options, Form 4, Director, Jennifer Jarrett, Beneficial Ownership, Derivative Securities